MX2014001271A - Tratamiento de diabetes de tipo 2 con fty720. - Google Patents

Tratamiento de diabetes de tipo 2 con fty720.

Info

Publication number
MX2014001271A
MX2014001271A MX2014001271A MX2014001271A MX2014001271A MX 2014001271 A MX2014001271 A MX 2014001271A MX 2014001271 A MX2014001271 A MX 2014001271A MX 2014001271 A MX2014001271 A MX 2014001271A MX 2014001271 A MX2014001271 A MX 2014001271A
Authority
MX
Mexico
Prior art keywords
fty720
diabetes
treatment
type
administering
Prior art date
Application number
MX2014001271A
Other languages
English (en)
Other versions
MX364643B (es
Inventor
Zhongmin Ma
Original Assignee
Zhongmin Ma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhongmin Ma filed Critical Zhongmin Ma
Publication of MX2014001271A publication Critical patent/MX2014001271A/es
Publication of MX364643B publication Critical patent/MX364643B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols

Abstract

La presente invención proporciona métodos terapéuticos para la prevención y tratamiento de diabetes de tipo 2, que comprende administrar al paciente una cantidad efectiva de FTY720 o un análogo.
MX2014001271A 2011-08-03 2012-08-03 USO DEL COMPUESTO FTY720: 2-amino - 2-[2-(4-octilfenil) etil] propano-1,3-diol (fingolimod) EN EL TRATAMIENTO DE PACIENTES CON DIABETES DE TIPO 2. MX364643B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161574441P 2011-08-03 2011-08-03
PCT/US2012/049565 WO2013020069A1 (en) 2011-08-03 2012-08-03 Treatment of type 2 diabetes with fty720

Publications (2)

Publication Number Publication Date
MX2014001271A true MX2014001271A (es) 2014-05-19
MX364643B MX364643B (es) 2019-05-03

Family

ID=46682917

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001271A MX364643B (es) 2011-08-03 2012-08-03 USO DEL COMPUESTO FTY720: 2-amino - 2-[2-(4-octilfenil) etil] propano-1,3-diol (fingolimod) EN EL TRATAMIENTO DE PACIENTES CON DIABETES DE TIPO 2.

Country Status (10)

Country Link
US (2) US8653026B2 (es)
EP (1) EP2739277B1 (es)
JP (1) JP2014521697A (es)
CN (1) CN103930101A (es)
AU (1) AU2012289921B2 (es)
CA (1) CA2843224C (es)
DK (1) DK2739277T3 (es)
HK (1) HK1198467A1 (es)
MX (1) MX364643B (es)
WO (1) WO2013020069A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112402610A (zh) * 2020-11-20 2021-02-26 睿阜隆(杭州)生物医药有限公司 1-磷酸鞘氨醇受体调节剂在制备治疗糖尿病的药物中的新用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627406B1 (en) 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
SI0990440T1 (sl) * 1997-02-27 2009-04-30 Novartis Ag Farmacevtski sestavek, ki obsega 2-amino-2-(2-(4-oktilfenil)etil)propan-1,3-diol, lecitin in saharid
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
WO2000047558A1 (fr) 1999-02-10 2000-08-17 Welfide Corporation Composes amide et leur utilisation medicinale
JP3790686B2 (ja) * 2001-08-03 2006-06-28 独立行政法人理化学研究所 血糖降下剤
DE60329724D1 (de) * 2002-06-07 2009-11-26 Waratah Pharmaceuticals Inc Methoden und Kompositionen um Diabetes zu behandeln
AU2003283004A1 (en) * 2002-10-22 2004-05-13 Waratah Pharmaceuticals, Inc. Treatment of diabetes
WO2009061374A2 (en) * 2007-11-02 2009-05-14 Concert Pharmaceuticals, Inc. Deuterated fingolimod

Also Published As

Publication number Publication date
US20140107024A1 (en) 2014-04-17
US8653026B2 (en) 2014-02-18
CN103930101A (zh) 2014-07-16
WO2013020069A1 (en) 2013-02-07
EP2739277A1 (en) 2014-06-11
AU2012289921A1 (en) 2014-02-06
MX364643B (es) 2019-05-03
JP2014521697A (ja) 2014-08-28
DK2739277T3 (en) 2017-02-27
NZ620025A (en) 2016-02-26
HK1198467A1 (en) 2015-05-08
EP2739277B1 (en) 2016-11-23
AU2012289921B2 (en) 2017-05-04
CA2843224A1 (en) 2013-02-07
CA2843224C (en) 2020-04-21
US20130123172A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
PH12020500352A1 (en) Therapeutic uses of empagliflozin
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
IN2014KN02830A (es)
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
MX2015008114A (es) Derivados de exendina-4.
GT201100118A (es) Compuestos de arilo con sustituyentes heterocíclicos como inhibidores hif
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
IN2012DN00624A (es)
EA201201657A1 (ru) Лечение диабета
UA113849C2 (xx) Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
IN2012DN06720A (es)
MX2014001050A (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero.
MX2013008192A (es) Inhibidores de bace-2 para tratamiento de transtornos metabolicos.
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
WO2012015758A3 (en) Methods of treating pain
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
NZ701607A (en) Therapeutic use of chardonnay seed products
MX360189B (es) Terapia de combinacion para el tratamiento de glioblastoma.
MX2012000006A (es) L-serina para usarse como un farmaco para prevenir y/o tratar una respuesta inflamatoria de la piel.
MX364220B (es) Metodos de tratamientos de fibrosis.
MX2016000220A (es) Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
MX2015000485A (es) Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina.
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
MX2014001271A (es) Tratamiento de diabetes de tipo 2 con fty720.
MX2014006990A (es) Tratamiento para diabetes tipo i y tipo ii.

Legal Events

Date Code Title Description
FG Grant or registration